EU projects
Pulsetto wins InoPažanga and secures EU funding
EU funding for clinical trials of the Pulsetto vagus nerve stimulator.
UAB “Pulsetto” is proud to announce our victory in the prestigious InoPažanga competition, securing European Union funding for our groundbreaking project. This initiative aims to validate the safety and efficacy of our innovative vagus nerve stimulator, Pulsetto, through rigorous clinical trials. Recognising that clinical trials are crucial for health tech innovation, we are dedicated to ensuring that Pulsetto meets the highest standards, providing customers with reliable, evidence-based technology.
What the project will deliver
Upon the project’s completion, we will have developed an innovative, high-quality vagus nerve stimulator poised to compete successfully in the market. Our Pulsetto device will be accessible to the public and is expected to significantly enhance the quality of daily life by effectively combating stress. Beyond promoting relaxation, Pulsetto will help regulate food intake and feelings of satiety, improve sleep quality, and reduce fatigue. A key outcome of the project is to validate the safety, efficacy, and suitability of the Pulsetto vagus nerve stimulator.
With the support of the European Union, UAB “Pulsetto” is committed to advancing health technology and improving lives through our innovative solutions.
Project details
| Detail | Information |
|---|---|
| Funding | European Regional Development Fund |
| Duration | 14 November 2023 – 9 October 2026 |
| Project value | 1,307,288.47 EUR |
| EU funding | 618,022.69 EUR |
| Administrative institution | Innovation Agency |
| Partner | UAB Pikotera |
More information: www.esinvesticijos.lt
Co-funded by the European Union
The project is financed by the European Regional Development Fund.